Pharmaceutical

Image

Global Hematologic Malignancies Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hematologic Malignancies Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 59.45 Billion
Diagram Market Size (Forecast Year) USD 138.99 Billion
Diagram CAGR %

Global Hematologic Malignancies Market, By Type (Leukaemia, Lymphoma, Myeloma), Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Diagnosis (Blood Tests, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size

In recent years, the hematologic malignancies market is anticipated to grow rapidly during the forecast period. As per the Globocan 2020 information sheet, there were an anticipated 19,292,789 new cancer cases identified globally, with about 9,958,133 cancer-related deaths. Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2040, the worldwide incidence of cancer would have increased to 27.5 million new cases and 16.3 million deaths. Hematological malignancies, often known as haematological cancer, are becoming more common around the world. According to the National Cancer Institute, hematological cancer is the fifth most frequent cancer worldwide and the second leading cause of cancer death in the United States. Researchers estimate the incidence of haematological malignancies to rise even more in the next years, resulting in a greater demand for treatment, which will significantly impact the haematological malignancies market.

Data Bridge Market Research analyses that the hematologic malignancies market was valued at USD 59.45 billion in 2021 and is expected to reach USD 138.99 billion by 2029, registering a CAGR of 11.20% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Cancers of the blood-producing cells, such as lymphoma, leukaemia, and multiple myeloma, are referred to as hematologic malignancies. Platelets, red blood cells (RBCs), and white blood cells (WBCs), all of which arise from hematopoietic stem and progenitor cells in the bone marrow, are responsible for oxygen transport, wound clotting and immune protection. Microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling are all used to diagnose hematologic malignancies.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Type (Leukaemia, Lymphoma, Myeloma), Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Diagnosis (Blood Tests, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Capsules, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (UK), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (US)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Hematologic Malignancies Market Dynamics

Drivers

  • Increasing prevalence of hematological cancer

The rising prevalence of hematological cancer is estimated to enhance the hematologic malignancies market's growth rate. Blood cancer is becoming more common, and people are becoming more aware of the disease's risk at an earlier stage. These are the main drivers driving the market. According to the Leukemia and Lymphoma Society, about one person in the United States is diagnosed with blood cancer every three minutes (LLS). Furthermore, the International Agency for Research on Cancer estimates that 10.1 lakh new cases were diagnosed in 2020, with 7 lakh deaths due to Hematologic Malignancies.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of hematologic malignancies market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Advancement in immunohistochemistry (IHC)

Hematologic malignancies can now be accurately detected by exposing tissue samples to diverse antibodies directed against cell molecules and antigens, thanks to developments in immunohistochemistry (IHC). This in turn, estimated to enhance the market's expansion during the forecast period of 2022-2029.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hematologic malignancies market. Additionally, changing lifestyle of people and rising geriatric population will result in the expansion of hematologic malignancies market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hematologic malignancies market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. The advent of new and more efficient diabetic treatment and monitoring products is estimated to boost the market's growth rate in the future. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hematologic malignancies market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hematologic malignancies market. Additionally, strict regulatory approvals of cancer therapeutics and lack of awareness among people about different types of cancer will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This hematologic malignancies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematologic malignancies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hematologic malignancies market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hematologic Malignancies Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. The COVID-19 outbreak had touched every element of cancer care and research, as screening and oncology care services were categorized as low-priority services in various nations throughout the world. Furthermore, various local and national-level limitations on the movement of persons and goods imposed by public and private authorities were shown to severely disrupt the pharmaceutical products and ingredients supply chain, hampering the hematologic malignancies market's growth. Also, due to pandemic, the temporary closure of numerous academic institutes and difficulty in delivering post-sales services had resulted in a reduced supply of cancer products to end users.

Recent Development

  • In April 2021, U.S. Food and Drug Administration (FDA) had granted orphan drug designation to CA-4948. It is a small-molecular inhibitor that targets an oncogenic isoform of a gene which is mainly expressed in individuals with acute myeloid leukaemia and myelodysplastic syndrome. According to Curis, Inc., Receiving orphan drug classification is a significant step forward in the company's objective to reduce or prevent cancer progression in patients with uncommon hematologic malignancies.
  • In February 2021, TG Therapeutics Inc. had announced accelerated approval of U.S. Food and Drug Administration (FDA) for its UKONIQ (umbralisib). It is an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon which is used for treating adult patients suffering from relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL).

Global Hematologic Malignancies Market Scope

The hematologic malignancies market is segmented on the basis of type, therapy, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

Therapy Type

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
    • Tyrosine kinase inhibitors
    • Proteasome inhibitor
    • B-cell lymphoma-2 protein inhibitor
    • Isocitrate dehydrogenase-1 inhibitor
    • Hedgehog pathway inhibitor
    • Others

Diagnosis

Dosage form

  • Tablets
  • Capsules
  • Injections
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Hematologic Malignancies Market Regional Analysis/Insights

The hematologic malignancies market is analysed and market size insights and trends are provided by country, type, therapy, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Hematologic malignancies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hematologic malignancies market because of the growing number of research and development activities and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, growing prevalence of blood cancer and rising geriatric population will further influence the market's growth rate in this region

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and increasing penetration of novel cancer drugs in this region. Also, the development of healthcare infrastructure and increasing disposable income will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hematologic Malignancies Market Share Analysis

The Hematologic malignancies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hematologic malignancies market.

Some of the major players operating in the hematologic malignancies market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • Allergan (Ireland)
  • AstraZeneca (UK)
  • AbbVie Inc. (US)
  • Johnson & Johnson Private Limited (US)
  • Cipla Inc. (US)  
  • Abbott (US)
  • Merck KGaA (Germany)
  • LEO Pharma A/S (Denmark)
  • Bausch Health Companies Inc. (Canada)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Hikma Pharmaceuticals PLC (UK)
  • Fresenius Kabi AG (Germany)
  • Amneal Pharmaceuticals LLC. (US)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The market value for Hematologic Malignancies Market is expected USD 138.99 billion by 2029.
The Hematologic Malignancies Market is to grow at a CAGR of 11.20% during the forecast by 2029.
The major players operating in the Hematologic Malignancies Market are GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (UK), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (US).
The major countries covered in the Hematologic Malignancies Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials